New mRNA HIV vaccine trial aims to train immune system to fight virus

NCT ID NCT06557785

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests two experimental mRNA vaccines designed to teach the body to make powerful antibodies that can neutralize many types of HIV. About 53 healthy adults without HIV will receive the vaccines to check safety and immune response. The goal is to see if the vaccines are safe and can start building a defense against HIV.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center (Site ID: 32077)

    Boston, Massachusetts, 02215, United States

  • Columbia P&S (Site ID: 30329)

    New York, New York, 10032, United States

  • New York Blood Center (Site ID: 31801)

    New York, New York, 10065, United States

  • Penn Prevention (Site ID: 30310)

    Philadelphia, Pennsylvania, 19104, United States

  • Seattle Vaccine and Prevention (Site ID: 30331)

    Seattle, Washington, 98104, United States

  • University of Pittsburgh (Site ID: 1001)

    Pittsburgh, Pennsylvania, 15213, United States

  • Vaccine Trial Centre, Mahidol University CRS (Site ID: 32021)

    Bangkok, Ratchathewi, 10400, Thailand